share_log

This Insider Has Just Sold Shares In Avanos Medical

This Insider Has Just Sold Shares In Avanos Medical

这位内部人士刚刚出售了Avanos Medical的股票
Simply Wall St ·  03/17 10:03

Anyone interested in Avanos Medical, Inc. (NYSE:AVNS) should probably be aware that the Senior VP, Michael Greiner, recently divested US$153k worth of shares in the company, at an average price of US$19.12 each. The eyebrow raising move amounted to a reduction of 15% in their holding.

任何对阿瓦诺斯医疗公司(纽约证券交易所代码:AVNS)感兴趣的人都应该知道,高级副总裁迈克尔·格雷纳最近以每股19.12美元的平均价格剥离了该公司价值15.3万美元的股份。令人惊讶的举动使他们的持股量减少了15%。

The Last 12 Months Of Insider Transactions At Avanos Medical

Avanos Medical 过去 12 个月的内幕交易

Notably, that recent sale by Michael Greiner is the biggest insider sale of Avanos Medical shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$19.09. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

值得注意的是,迈克尔·格雷纳最近的出售是我们去年对Avanos Medical股票的最大一次内幕出售。因此,我们知道一位内部人士以目前的19.09美元左右的股价出售了股票。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。在这种情况下,大甩卖是在当前价格左右进行的,因此还不错(但仍然不是积极的)。

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

您可以看到下图所示的去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了,卖了多少钱,什么时候卖了,只需点击下面的图表即可!

insider-trading-volume
NYSE:AVNS Insider Trading Volume March 17th 2024
纽约证券交易所:AVNS 内幕交易量 2024 年 3 月 17 日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。

Insider Ownership Of Avanos Medical

Avanos Medical的内部所有权

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Avanos Medical insiders own 1.3% of the company, worth about US$11m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

许多投资者喜欢查看公司内部人士拥有多少股份。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。看来阿瓦诺斯医疗内部人士拥有该公司1.3%的股份,价值约1100万美元。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东之间的一致性。

So What Do The Avanos Medical Insider Transactions Indicate?

那么,阿瓦诺斯医疗内幕交易表明了什么呢?

Unfortunately, there has been more insider selling of Avanos Medical stock, than buying, in the last three months. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with Avanos Medical and understanding it should be part of your investment process.

不幸的是,在过去的三个月中,Avanos Medical股票的内幕抛售多于买入的股票。放大一点,长远的画面并不能给我们带来太大的安慰。尽管内部人士确实拥有股票,但他们并不拥有大量股票,他们一直在抛售。我们并不急于购买!因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。在投资风险方面,我们已经向Avanos Medical确定了一个警告信号,并知道这应该是您投资过程的一部分。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发